Suchergebnisse - "Bylicki, Olivier"

PubPharm (7)

1

First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors : New Combinations and Long-Term Data

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2022

von Boussageon, M. | Swalduz, A. | Chouaïd, C. | +1

ErratumIn: BioDrugs. 2023 Jan;37(1):121. - PMID 36401075

2

ROS-1 Fusions in Non-Small-Cell Lung Cancer : Evidence to Date

enthalten in: Current oncology (Toronto, Ont.) | 2022

von Gendarme, S. | Bylicki, O. | Chouaid, C. | +1

3

Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer : Evidence to Date

enthalten in: OncoTargets and therapy | 2020

von Bylicki, O. | Paleiron, N. | Assié, J. | +1

4

First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2019

von Bylicki, O. | Barazzutti, H. | Paleiron, N. | +3

5

New PDL1 inhibitors for non-small cell lung cancer : focus on pembrolizumab

enthalten in: OncoTargets and therapy | 2018

von Bylicki, O. | Paleiron, N. | Rousseau-Bussac, G. | +1

6

Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer

enthalten in: Targeted oncology | 2017

von Bylicki, O. | Paleiron, N. | Margery, J. | +6

7

Targeted therapy for localized non-small-cell lung cancer : a review

enthalten in: OncoTargets and therapy | 2016

von Paleiron, N. | Bylicki, O. | André, M. | +4

1
[1]